Novo Nordisk -- How the Business Works

Novo Nordisk is one of two companies that dominate the global GLP-1 receptor agonist market, forming a duopoly with Eli Lilly. The company discovers, develops, and manufactures injectable and oral therapies for diabetes, obesity, and rare diseases. Semaglutide -- sold as Ozempic for diabetes and Wegovy for obesity -- is the single most important drug franchise in the portfolio, generating DKK 206B in combined 2025 revenue. Novo acquired Catalent for $16.5B to vertically integrate its fill-finish manufacturing capacity. 2025 full-year revenue reached DKK 309B, with Diabetes and Obesity Care representing 93.7% of total sales. The GLP-1 market is projected to exceed $200B by 2030, but Novo is losing share to Lilly.

GLP-1 is a textbook duopoly with the deepest regulatory moat in pharma. Two companies -- Novo Nordisk and Eli Lilly -- control virtually the entire GLP-1 receptor agonist market for both diabetes and obesity. Developing a competing GLP-1 drug requires a decade of clinical trials, billions in investment, and FDA approval -- barriers that have kept all other pharmaceutical companies on the sidelines. The closest potential entrants (Amgen, Pfizer, Viking Therapeutics) are years away from commercialization. This structural duopoly means the $200B+ TAM will be split primarily between two players for at least the next 5-7 years, providing a floor on market share even for the weaker competitor.

Semaglutide concentration is both the strength and the vulnerability. Ozempic and Wegovy are both semaglutide -- the same molecule sold for different indications. Together they generated DKK 206B in 2025, representing two-thirds of total company revenue. This extreme concentration on a single molecule means that any competitive, regulatory, or patent challenge to semaglutide threatens the entire business. Semaglutide patent expiry is beginning in certain international markets (Canada first) starting 2026, with management guiding low single-digit group sales impact. The pipeline must deliver next-generation molecules (CagriSema, zenagamtide) to sustain growth beyond semaglutide maturity.

The price-for-volume trade is the defining strategic bet of the Doustdar era. New CEO Mike Doustdar has aggressively cut prices to expand patient access -- Wegovy self-pay at $199/month, Medicare pricing at $245/month through MFN. The thesis is that lower prices unlock vastly more patients (especially with Medicare Part D starting mid-2026), and the volume growth more than offsets the price decline. The 2026 guidance of -5% to -13% adjusted sales growth tells you this trade has not yet balanced. Management called the Wegovy pill launch "phenomenal" with 170K patients in month one. If volume inflects as management expects, this could be a temporary trough. If it does not, Novo faces structural margin compression in a two-player market where Lilly is not cutting prices as aggressively.

Catalent gives Novo control of manufacturing but at a near-term financial cost. The $16.5B Catalent acquisition in Q4 2024 was a strategic decision to vertically integrate fill-finish manufacturing -- the bottleneck that constrained Wegovy supply in 2022-2023. The financial impact has been severe: FCF went negative (DKK -14.7B) in 2024, gross margins compressed 370 basis points to 81.0% in 2025 from Catalent depreciation and restructuring, and DKK 55B in guided 2026 capex continues to constrain free cash flow. The long-term logic is sound -- owning your manufacturing when demand could 5-10x over the next decade eliminates supply chain risk. But investors are paying the cost now while the benefits are years away. The Catalent absorption, combined with pricing pressure and competitive share loss, explains why NVO trades at just 10x trailing earnings -- a historically cheap valuation for a GLP-1 oligopoly leader that reflects genuine uncertainty about the path from here.